Unlisted Deals:
×

Pharmed Ltd Annual Report & Financials

Last Traded Price 650.00 + 0.00 %

Pharmed Limited (Pharmed Limited) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Pharmed Limited

PHARMED Limited Consolidated Balance Sheet (In Rs. Crores)

Particulars

As at 31 March 2023

As at 31 March 2022

ASSETS                        

 

 

1) Non current assets

 

 

a)Property, Plant, and Equipment

 

 

i) Property, Plant, and Equipment

                               47.54

                               49.73

ii) Intangible Assets

                                 0.10

                                 0.12

iii) Capital work in progress

                                 0.31

                                 0.31

b) Goodwill on consolidation

                               29.11

                               29.11

c) Non current investments

                             141.06

                             113.72

c) Deferred Tax Assets (Net)

                                 2.44

                                 2.55

d) Other Non-Current Assets

                                 0.58

                                 0.49

Total non current assets

                             221.14

                             196.03

Current Assets

 

 

a) Inventories

                               31.02

                               32.24

b)  Trade Receivables

                               18.83

                               17.26

c) Cash and Cash Equivalents

                               12.73

                                 4.42

d) Short Term Loans and Advances

                                 6.06

                               12.26

Total current assets

                               68.64

                               66.18

Total Assets

                             289.78

                             262.21

EQUITY AND LIABILITIES

 

 

EQUITY

 

 

a) Equity Share capital

                                 0.86

                                 0.86

b) Other equity

                             230.19

                             198.74

Total Equity

                             231.05

                             199.60

LIABILITIES

 

 

Non-current Liabilities

 

 

a) Other Long Term liabilities

                                 4.26

                                 2.83

b) Long Trem Provisions

                                 4.99

                                 4.53

Total non current liabilities

                                 9.25

                                 7.36

Current liabilities

 

 

a)Trade payables

 

 

 Total outstanding dues of micro and small Enterprises

                               20.24

                               24.06

Total outstanding dues of creditors other than micro and small enterprises

                                 3.71

                               12.56

b) Other current liabilities

                                 4.27

                                 5.81

c) Short Term Provisions

                               21.26

                               12.82

Total current liailities

                               49.48

                               55.25

Total liabilities

                               58.73

                               62.61

Total Equity and liabilities

                             289.78

                             262.21

PHARMED  Limited Consolidated Profit & Loss Statement (In Rs. Crores)

 

PARTICULARS

2023

2022

 Revenue from Operations

              425.99

              350.19

 Other Income

                  9.98

                  9.45

 Total Revenue

             435.97

             359.64

 Expenses

 

 

Purchase of Stock in Trade

              127.66

              100.37

Changes In Inventories of Stock in Trade

                  1.22

                -6.25

Employee Benefits Expense

              129.97

                97.79

Finance Cost

                  0.36

                  0.30

Other Expenses

              130.39

              110.09

Depreciation and Amortisation Expense

                  3.27

                  2.32

Total Expenses

             392.87

             304.62

Profit before Tax 

               43.10

               55.02

Tax Expense

 

 

1) Current Tax

                10.03

                13.08

2) Deferred Tax

                  0.10

                -0.39

Profit for the year

               32.97

               42.33

Earnings per Equity share (Face Value Per Share)

 

 

a) Basic (Rs.)

                76.54

                98.27

b) Diluted (Rs.)

                76.54

                98.27

PHARMED Limited Consolidated Cash Flow Statement (In Rs. Crores)

 

Particulars

 31st March 2023

 31 March 2022 

A. Cash Flow from Operating Activities

 

 

Profit/(Loss) Before Tax 

                43.10

                55.02

Adjustments for:

 

 

Depreciation and amortisation expenses

                  3.27

                  2.32

Finance cost

                  0.36

                  0.30

Interest Income

                -0.81

                -0.70

Net(gain) / Loss on sale of Investments

                -8.62

                -7.83

Rental Income from Investment Properties

                -0.04

                -0.04

(Gain) / Loss on sale of Asset

                  0.01

                  0.01

Cash generated from operations before working capital changes

               37.27

               49.08

Working capital changes

 

 

Adjustments for (increase)/decrease in operating Assets

 

 

Inventories

                  1.22

                -6.25

Trade receivables 

                -1.57

                -0.93

Short term loan and advances

                  5.06

                -5.23

Long term Loans and advances

                     -  

                  1.20

Other non current assets

                -0.09

                -0.16

Adjustments for (increase)/decrease in operating liabilities

 

 

Trade payables

               -12.66

                12.56

Other current liabilities

                -1.54

                  2.73

Other Long term liabilities

                  1.43

                  0.30

Long term provisions

                  0.44

                  0.64

Short Term provisions

                  8.44

                -0.07

Operating profit after working capital changes

               38.00

               53.87

Income tax paid, net of refunds

                -8.99

               -14.12

Net cash generated from operating activities

               29.01

               39.75

Cash flows from investing activities

 

 

Capital Expenditure on Fixed Assets, including capital advances

                -1.13

               -41.97

Proceeds from sale of property, plant & equipment

                  0.06

                  0.55

Purchase of long term investments

             -104.55

               -49.48

Proceeds from sale of long term investments

                85.83

                52.13

Interest Received

                  0.81

                  0.70

Rental Income Received

                  0.04

                  0.04

Net cash used in investing activities

              -18.94

              -38.03

Cash flows from financing activities

 

 

Dividend paid

                -0.36

                -0.30

Finance cost

                -1.51

                -3.01

Tax on Dividend

 

 

Net cash used in financing activities

                -1.87

                -3.31

Net increase/ (decrease) in cash and cash equivalent 

                 8.20

                -1.59

Add: Cash and Cash Equivalent at beginning of year

                  4.35

                  5.94

Cash and cash equivalents as at end of year

               12.55

                 4.35

Cash and Cash Equivalent comprise the following

 

 

Cash on hand

                  0.08

                  0.16

Balance with bank

 

 

 In Current Account

                12.65

                  4.27

Total

                12.73

                  4.43

PHARMED Limited Key Financial Ratios ( Standalone)

 

Particulars

31-Mar-23

31-Mar-22

Current Ratio (in times)

1.4

1.21

Debt-Equity Ratio (in times)

0

0

Debt Service Coverage Ratio (in times)

0

0

Return on Equity Ratio (in %)

14.44%

21.41%

Inventory Turnover Ratio (in times)

13.47

12.03

Trade Receivables Turnover Ratio (in times)

23.61

20.85

Trade Payable Turnover Ratio (in times)

4.22

3.31

Net Capital Turnover Ratio (in times)

27.45

26.89

Net Profit Ratio (in %)

7.77%

12.08%

Return on investment

6.74%

7.57%

Return on Capital Employed Ratio (in %)

19.00%

28.00%

PHARMED  Limited share Dividend History

 

Particulars 2023 2022
Dividend per Share 3.5 3.5
Retained Earnings (In Rs. Crores) 228.4 196.81

PHARMED  Limited Recent Financial Performance for FY 2023

 

Revenue from Operations: Revenue increased by ₹75.80 crores from 2022 to 2023, indicating potential growth in the core business.

Other Income: Other income remained relatively stable, with a slight increase from ₹9.45 crores in 2022 to ₹9.98 crores in 2023.

Total Revenue: Total revenue increased by ₹76.33 crores from 2022 to 2023, reflecting both core business growth and stable other income.

Total Expenses: Total expenses increased from ₹304.62 crores in 2022 to ₹392.87 crores in 2023, possibly due to increased costs.

Profit before Tax: Profit before tax decreased by ₹11.92 crores from 2022 to 2023, indicating lower pre-tax profitability in 2023.

Profit for the Year: The profit for the year decreased by ₹9.36 crores from 2022 to 2023.

Earning per Equity Share - Basic and Diluted: Basic and diluted earnings per equity share decreased significantly from ₹98.27 in 2022 to ₹76.54 in 2023, indicating reduced earnings per share.

 

 

Pharmed Limited Annual Report

Pharmed Limited Annual Report 2022-23

Download

Pharmed Limited Annual Report 2021-22

Download
Support Megha Support Neha

News Alert